Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an $41 million insider trading and stock manipulation scheme that involves two biotech ...

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...

Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time. | Ipsen may be a recent entrant into the antibody-drug conjugate ...

Having kicked off the year with a $200 million series A, Windward Bio is ending 2025 splashing out on another clinical-stage drug. | Having kicked off the year with a $200 million series A, Windward ...

Hologic has put forward more data bolstering the use of its artificial intelligence programs for detecting breast cancer through mammography. | Hologic put forward another study that bolsters the use ...

U.K.-based AstraZeneca has scored the exclusive rights to develop and commercialize the pan-KRAS inhibitor, dubbed JAB-23E73, outside China. On Jacobio’s home territory, the Beijing-headquartered ...

Susan Galbraith, AstraZeneca’s executive vice president for oncology haematology R&D, discussed the setback in a statement. Galbraith said the goal was to “reinvigorate the immune response of patients ...